Real-World Use of Systemic Therapies for the Treatment of Advanced Thyroid Cancers
Authors' conclusion
Between 2013 and 2021, the use of systemic treatment options for advanced thyroid cancer increased significantly, largely driven by the prescription of lenvatinib following its approval by the FDA in 2015, with an increasing trend for use in non-White patients.
Study context
- Population
- Patients treated with systemic therapy (15 agents) for advanced thyroid cancer, 2013–2021, Optum's de-identified Clinformatics Data Mart Database
- Participants
- 885 patients
- Outcome
- Trends in use of systemic therapies for advanced thyroid cancer
- Follow-up
- 2013–2021
Methodological detailsclaims database (Optum Clinformatics Data Mart), joinpoint regression
- Claims database (Optum Clinformatics Data Mart)
- Joinpoint regression
Main finding
As reported in the abstract
Use of systemic therapy for advanced thyroid cancer
- Annual number of patients treated with systemic therapy, 2013 to 2021
- 45 to 114
- Proportion of non-Hispanic White patients treated: annual percentage change
- −3.9% (−6.0% to −1.8%) (95% CI)
- Lenvatinib as first-line therapy for radioiodine-refractory thyroid cancer, 2017–2021
- 48.8%
- Initiated on 1 of the 10 Food and Drug Administration (FDA)-approved agents, 2017–2021
- 79.7%
- Received only a first-line therapy, 2017–2021
- 81.7%
Observational data: associations, not effects.
Further findings
Patient characteristics
- Female
- 54.7%
- Non-Hispanic White
- 62.1%
Original publication
Real-World Use of Systemic Therapies for the Treatment of Advanced Thyroid Cancers. Endocr Pract. Published 23 August 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →